2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. boosted its holdings in 2seventy bio, Inc. (NASDAQ:TSVT) by 512.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,508,800 shares of the company’s stock after acquiring an additional 3,772,556 shares during the period. Goldman Sachs Group Inc. owned 8.91% of 2seventy bio worth $19,253,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in shares of 2seventy bio in the third quarter valued at approximately $339,000. Acadian Asset Management LLC purchased a new position in 2seventy bio during the third quarter worth $89,000. Trexquant Investment LP raised its holdings in shares of 2seventy bio by 43.3% in the third quarter. Trexquant Investment LP now owns 73,338 shares of the company’s stock worth $287,000 after acquiring an additional 22,172 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of 2seventy bio in the third quarter valued at $225,000. Finally, Newtyn Management LLC lifted its position in shares of 2seventy bio by 317.0% in the third quarter. Newtyn Management LLC now owns 3,076,490 shares of the company’s stock valued at $12,060,000 after acquiring an additional 2,338,746 shares in the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

2seventy bio Trading Down 4.3 %

TSVT stock opened at $3.60 on Thursday. The company has a market cap of $185.04 million, a PE ratio of -0.83 and a beta of 1.80. The stock has a 50-day moving average price of $4.35 and a two-hundred day moving average price of $4.53. 2seventy bio, Inc. has a 12-month low of $1.53 and a 12-month high of $11.29.

2seventy bio (NASDAQ:TSVT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The firm had revenue of $12.44 million for the quarter, compared to analysts’ expectations of $11.93 million. 2seventy bio had a negative return on equity of 67.59% and a negative net margin of 313.51%. Equities analysts forecast that 2seventy bio, Inc. will post -0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TSVT shares. Citigroup boosted their target price on shares of 2seventy bio from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, April 8th. The Goldman Sachs Group downgraded shares of 2seventy bio from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $5.00 to $2.00 in a research note on Thursday, June 6th. Canaccord Genuity Group lowered their target price on shares of 2seventy bio from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Canaccord Genuity Group raised 2seventy bio to a “strong-buy” rating in a research note on Thursday, May 9th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of 2seventy bio in a research report on Monday, March 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.43.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.